BioMarin Pharmaceutical Inc. (BMRN)

NMS – Цена в реальном времени. Валюта: USD

52.88

+0.30 (0.57%)

При закрытии: May 12, 2026, 4:00 PM EDT

52.85

-0.03 (-0.06%)

До открытия: May 13, 2026, 8:57 AM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

BioMarin Pharmaceutical Inc. (BMRN)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

BioMarin Pharmaceutical Inc. (BMRN)

BioMarin: 'Strong Buy' On VOXZOGO Expansion And Amicus Acquisition

BioMarin Q1 Earnings Miss, Sales Beat, '26 Revenue Guidance Raised

BioMarin Pharmaceutical Inc. (BMRN) Q1 2026 Earnings Call Transcript

Compared to Estimates, BioMarin (BMRN) Q1 Earnings: A Look at Key Metrics

BioMarin Pharmaceutical (BMRN) Q1 Earnings Lag Estimates

BioMarin Reports First Quarter 2026 Financial and Operating Results

BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual Meeting

Видео

No Data

Пресс-релизы

BioMarin Reports First Quarter 2026 Financial and Operating Results

BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual Meeting

BioMarin Completes Acquisition of Amicus Therapeutics

BioMarin Announces Board Leadership Transition

Search stocks

BioMarin Pharmaceutical Inc. (BMRN)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

BioMarin Pharmaceutical Inc. (BMRN)

BioMarin: 'Strong Buy' On VOXZOGO Expansion And Amicus Acquisition

BioMarin Q1 Earnings Miss, Sales Beat, '26 Revenue Guidance Raised

BioMarin Pharmaceutical Inc. (BMRN) Q1 2026 Earnings Call Transcript

Compared to Estimates, BioMarin (BMRN) Q1 Earnings: A Look at Key Metrics

BioMarin Pharmaceutical (BMRN) Q1 Earnings Lag Estimates

BioMarin Reports First Quarter 2026 Financial and Operating Results

BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual Meeting

Видео

No Data

Пресс-релизы

BioMarin Reports First Quarter 2026 Financial and Operating Results

BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual Meeting

BioMarin Completes Acquisition of Amicus Therapeutics

BioMarin Announces Board Leadership Transition